



CREATING A FUTURE WHERE TIMELY INTERVENTION IS THE NORM



Quantitative Alzheimer's
triage and monitoring

Sciflux develops diagnostic tests, to help healthcare providers achieve **quantitative** neurodegenerative disease **monitoring** from blood, using our multiparametric biomarker analysis approach.

Alzheimer's care has entered a treatment era — but we still **lack a scalable way to quantitatively monitor disease trajectory.**

Families are forced to make life-changing decisions without data, while health systems absorb the downstream costs. The human toll is immeasurable: imagine your mom/dad slowly forgetting who you are.



Every 3 seconds

a loved one develops dementia



<2%

dementia patients receive biomarker testing *



>86 million

people globally with cognitive decline symptoms



3X more

Alzheimer cases by 2050

* 2% of individuals in the UK are being diagnosed using CSF or PET

Quantitative monitoring for Alzheimer's is lagging behind

Available blood tests are ***screening only***

Current protein tests focus on **screening** due to their **binary output**, which doesn't capture disease state.

Current monitoring is ***expensive & inaccessible***

True monitoring options, such as PET imaging, are **costly** and **inaccessible** at scale, excluding them from routine care.

RESULT ⇒ **Diagnosis is delayed** and longitudinal **monitoring** is largely **absent** — leaving patients, clinicians, and pharma blind to disease trajectory.

WE WILL CHANGE THAT

Our blood test, allows to **triage patients** with cognitive symptoms and **track** Alzheimer's disease **progression**. We will make testing:

QUANTITATIVE



FAST &
ACCESSIBLE



COST-
EFFECTIVE




MINIMALLY
INVASIVE



RESULT: a clear, quantitative view of disease progression and treatment response → giving patients, doctors, and pharma the **info to act for the first time**. Saving **lives** and **money**¹

WHY NOW?



Experienced and relevant founding team

UNFAIR ADVANTAGE

Silver is a biophysicist with non-obvious engineering insights on biomarker detection.

Sten has extensive business building experience taking multiple hardware products from inception to market.

We are a motivated duo (known ~2 decades), complementing our skill-sets with respected KOLs in diagnostics and healthcare:

ADVISORS

Diagnostics

Samuel Woodhouse, PhD, Head of Biopharma Diagnostics, AstraZeneca; brought several diagnostics from concept to market (\$400M exit)


Biotech

Gavin Jeffries, PhD, CTO and Co-Founder of Fluicell AB (IPO in 2018), 6 patent families, 3900 citations. Offers lab facilities.

Clinical & AI

Mihkel Arrak, MD, 5 years of primary healthcare experience, 3 years of clinical trial regulation, and medical AI expert.

CEO



Silver Jõemetsa

PhD in Materials Science with a decade of experience in developing highly innovative tools for detecting and characterizing biomarkers.

[List of publications](#)

 **Scripps Research**

COO



Sten Krüüner

Robotics engineer turned startup operator building real robots that ship. Veteran of 3 market leading startups and over \$50M in products delivered, helping drive millions in market value.

Parcelsea 
CLEVERON  **MILREM
ROBOTICS**

Differentiated detection approach

Our microfluidics-based platform:



- **QUANTITATIVE** by measuring **multiple parameters**¹, something single-protein platforms cannot achieve
- Focuses on extracellular vesicles (EV), small particles shed by cells
- **Subpopulation** selectivity without extra sample preparation²
- Independent and synergistic with current tests, positioning downstream

De-risked technology


- ✓ Commercializing established EV biology
- ✓ Our platform's functionality proven with **Scripps** partnership
- ✓ We have shown analytical **feasibility in human blood** plasma
- ✓ **Proprietary** method coupled with off-the-shelf devices (trade secret + IP)

What this enables

- ① **Monitor progression** and treatment response
- ② **Capture** disease state
- ③ **>6X cheaper** and **10X faster** than a PET scan
- ④ Expand to a **pan-neuro pipeline** (same platform – multiple neuro diseases)

Wedge to Market via KOLs


Customer discovery (100+) highlights the need for **monitoring and triage** at private and memory clinics.



The main risks are **market acceptance** and **sample access**. Partners are already waiting to send us samples.

Current clinical collaborations

Demand for our technology has allowed us to establish **clinical sample** access with global partners.



NorCog, Oslo Uni Hospital
Norway
Prof. Ole Andreassen, MD


Confido Medical Centre
Estonia
Prof. Toomas Toomsoo, MD

Upcoming:
ADNI (leading AD sample consortium) and **UCSD**, USA
Prof. Anders Dale, PhD

Cha Medical University
Korea
Prof. Jisook Moon, PhD

GTM/Business Model

B2B service (LDT) for neurologist at memory clinics for disease monitoring



\$600/test, 100 tests/month/clinic. Unit cost ~ \$100

***MRD for Neuro:** We are following the well-trodden path of reimbursable cancer monitoring (>\$900 per test) for patients with cognitive issues.*

Huge market, massive need, well-trodden

\$1.3 trillion

Annual cost of dementia
of which \$360B is direct total payments (in US)



(ADI)

*Market penetration
(Natera)*

Lower estimate

18% x 2 tests/year x \$600 x 6M patients (US) = **\$1.3B ARR**

*Reimbursed at these
levels by CMS*

After addressing Alzheimer's, we plan to scale the team and expand our platform into other neuro diseases, incl. Parkinson's (PD) and ALS.


Market size will

2X
by 2030




(GVR 2025)

Roadmap to delivery



Vision

We are building the future standard of care for neurodegenerative diseases.
Now is the time to invest.





A future where timely intervention is the norm

Want to know more?

CONTACT US



[in/sjoemetsa](https://www.linkedin.com/company/sciflux)
[in/stenkryner](https://www.linkedin.com/company/sciflux)

silver@sciflux.tech
sten@sciflux.tech